A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Must have received: immunomodulatory drug

prior lines of therapy that include an immunomodulatory drug (IMiD)

Must have received: proteasome inhibitor

prior lines of therapy that include...a proteasome inhibitor

Must have received: anti-CD38 mAb

prior lines of therapy that include...an anti-CD38 mAb

Must have received: T-cell redirecting therapy

prior lines of therapy that include...a T-cell redirecting therapy (TRT, eg, a CAR-T or T-cell engaging bispecific treatment) unless the participant is not a candidate for TRT

Cannot have received: CC-92480 (CC-92480)

For Part 1: received prior therapy with CC-92480

Cannot have received: CC-92480 (CC-92480)

For Part 2: received prior therapy with CC-92480

Cannot have received: EZH2 inhibitor (tazemetostat)

For Part 2: received prior therapy with tazemetostat

Cannot have received: BET inhibitor (BMS-986158)

For Part 2: received prior therapy with BMS-986158

Cannot have received: MEK inhibitor (trametinib)

For Part 2: received prior therapy with trametinib

Cannot have received: allogeneic stem cell transplant

Previously received allogeneic stem-cell transplant at any time

Cannot have received: autologous stem cell transplant

Exception: within 12 weeks of initiating study treatment

received autologous stem-cell transplant within 12 weeks of initiating study treatment

Cannot have received: plasmapheresis

Exception: within 14 days prior to initiating study treatment

Received any of the following within 14 days prior to initiating study treatment: Plasmapheresis

Cannot have received: major surgery

Exception: within 14 days prior to initiating study treatment

Received any of the following within 14 days prior to initiating study treatment: Major surgery

Cannot have received: radiation therapy

Exception: within 14 days prior to initiating study treatment, except local therapy for myeloma associated bone lesions

Received any of the following within 14 days prior to initiating study treatment: Radiation therapy other than local therapy for myeloma associated bone lesions

Cannot have received: systemic anti-myeloma drug therapy

Exception: within 14 days prior to initiating study treatment

Received any of the following within 14 days prior to initiating study treatment: Use of any systemic anti-myeloma drug therapy

Cannot have received: investigational agent

Exception: within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment

Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment